Drugs / BPSC1001
BPSC1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02374385 | Nov 2014 → Mar 2015 | Filoviridae infectious disease | Dalhousie University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPSC1001 | “To study the anti-Ebola vaccine VSV ZEBOV (BPSC1001) to see if it is safe.” NCT02374385 ↗ |
| Known as | VSV ZEBOV | “To study the anti-Ebola vaccine VSV ZEBOV (BPSC1001) to see if it is safe.” NCT02374385 ↗ |
| Known as | VSVΔG-ZEBOV | “BPSC-1001 (VSVΔG-ZEBOV)” NCT02374385 ↗ |
| Modality | Vaccine | “Ebola Virus Vaccine” NCT02374385 ↗ |
| Route | Intramuscular | “The vaccine or placebo will be injected into the upper arm muscle.” NCT02374385 ↗ |